1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
606C1CD857FF4E87085256F630055FCAB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/re-launching-products-key-findings-insights?opendocument
18
19opendocument
203.91.106.44
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Re-launch

Product Re-Launch Success: Key Findings

DB Image

ID: 4772


Features:


Pages/Slides: 5


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"Product Re-Launch Success: Key Findings"


Study Overview
Re-launching a pharmaceutical product is a marketing challenge that no brand executive wants to face, but many often do. With millions of dollars poured into the development and marketing of products, companies are loathe to give up their initial investment, but they also are hesitant to waste further resources to correct mistakes. This five-page document summarizes for brand executives major key findings and insights on re-launching pharmaceutical products.

Key topics

  • Setting re-launch strategy -- assessing what went wrong and building the business case
  • Setting the pathway to success
  • Redefining product character and positioning
  • Winning the hearts and minds of the sales organization
  • Winning the marketing resource investments to succeed

Methodology
This document originated from a larger consulting project for a major pharmaceutical client. It is based on a study of over 15 pharmaceutical and biotech companies.

Industries Profiled:
Consumer Products; Diagnostic; Pharmaceutical; Medical Device; Biotech; Health Care


Companies Profiled:
Bayer Healthcare; UCB Pharma; Schering-Plough; Roche; Pfizer; Novartis; Merck; AstraZeneca; DSM Pharmaceutical; Sanofi-aventis; Abbott Laboratories; Eli Lilly; GlaxoSmithKline l

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.